Literature DB >> 10475400

An essential role for NF-kappaB in the cardioadaptive response to ischemia.

E N Morgan1, E M Boyle, W Yun, J M Griscavage-Ennis, A L Farr, T G Canty, T H Pohlman, E D Verrier.   

Abstract

BACKGROUND: Ischemic preconditioning (IP) is the phenomenon whereby brief episodes of ischemia protect the heart against a subsequent ischemic stress. We hypothesize that activation of the transcription factor NF-kappaB mediates IP.
METHODS: Rabbits were randomly allocated to one of three groups: (1) 45 minutes of myocardial ischemia followed by 2 hours of reperfusion (I/R); (2) three cycles of 5-minute ischemia and 5 minutes of reperfusion followed by I/R (IP + I/R); or (3) IP in the presence of ProDTC, a specific NF-kappaB inhibitor, followed by I/R (IPProDTC + I/R). Infarct size, indices of regional contractility, and NF-kappaB activation were determined.
RESULTS: In preconditioned rabbits (IP + I/R), infarct size was reduced 83% compared with both I/R alone and IPProDTC + I/R groups (p < 0.05). Throughout reperfusion, preconditioned myocardium showed enhanced regional contractile function compared with I/R and IPProDTC + I/R groups (p < 0.05). Gel shift analysis showed NF-kappaB activation with IP that was blocked by ProDTC. I/R and IPProDTC + I/R groups showed NF-kappaB activation with I/R that was absent in preconditioned animals.
CONCLUSIONS: The cytoprotective effects induced by IP require activation of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475400     DOI: 10.1016/s0003-4975(99)00646-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

1.  Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury.

Authors:  Stefan Frantz; Jochen Tillmanns; Peter J Kuhlencordt; Isabel Schmidt; Anna Adamek; Charlotte Dienesch; Thomas Thum; Steve Gerondakis; Georg Ertl; Johann Bauersachs
Journal:  Am J Pathol       Date:  2007-06-07       Impact factor: 4.307

2.  microRNA expression and its potential role in cardioprotection by ischemic postconditioning in pigs.

Authors:  Theodor Baars; Andreas Skyschally; Ludger Klein-Hitpass; Elke Cario; Raimund Erbel; Gerd Heusch; Petra Kleinbongard
Journal:  Pflugers Arch       Date:  2014-01-05       Impact factor: 3.657

3.  Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium.

Authors:  Adrienn Kis; Derek M Yellon; Gary F Baxter
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice.

Authors:  David Young; Zoran B Popovic; W Keith Jones; Sudhiranjan Gupta
Journal:  J Mol Biol       Date:  2008-06-05       Impact factor: 5.469

5.  Imperatorin Relieved Ulcerative Colitis by Regulating the Nrf-2/ARE/HO-1 Pathway in Rats.

Authors:  Min Luo; Yin Luo
Journal:  Inflammation       Date:  2020-10-23       Impact factor: 4.092

6.  Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart.

Authors:  Harjot K Saini; Yan-Jun Xu; Ming Zhang; Peter P Liu; Lorrie A Kirshenbaum; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2005

7.  The role of free radicals in endogenous adaptation and intracellular signals.

Authors:  E Röth; L Hejjel; Mt Jaberansari; G Jancso
Journal:  Exp Clin Cardiol       Date:  2004

8.  IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation.

Authors:  Chenguang Fan; Qiang Li; Yulong Zhang; Xiaoming Liu; Meihui Luo; Duane Abbott; Weihong Zhou; John F Engelhardt
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

9.  Innate immunity and remodelling.

Authors:  Guro Valen
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

Review 10.  Post-infarct remodelling: contribution of wound healing and inflammation.

Authors:  Stefan Frantz; Johann Bauersachs; Georg Ertl
Journal:  Cardiovasc Res       Date:  2008-10-31       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.